
Rare Pediatric Disease Priority Review Vouchers, Guidance for Industry

DRAFT GUIDANCE

**This guidance document is being distributed for comment purposes only.
Document issued on: November 17, 2014**

You should submit comments and suggestions regarding this draft document within 90 days of publication in the *Federal Register* of the notice announcing the availability of the draft guidance. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to <http://www.regulations.gov>. All comments should be identified with the docket number listed in the notice of availability that publishes in the *Federal Register*.

For questions regarding this document, contact **Henry Startzman, III, M.D., [301-796-8660]**

**U.S. Department of Health and Human Services
Food and Drug Administration
Center for Biologics Evaluation and Research (CBER)
Center for Drug Evaluation and Research (CDER)
Office of Orphan Products Development (OOPD)**

November 17, 2014

Additional copies are available from:

Office of Communications, Division of Drug Information
Center for Drug Evaluation and Research
Food and Drug Administration
10903 New Hampshire Ave., Bldg. 51, rm. 2201
Silver Spring, MD 20993-0002

Tel: 301-796-3400; Fax: 301-847-8714; E-mail: druginfo@fda.hhs.gov
<http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm>

or

Office of Communication, Outreach, and Development
Center for Biologics Evaluation and Research
Food and Drug Administration
10903 New Hampshire Avenue, Bldg. 71, rm. 3128
Silver Spring, MD 20993-0002

Tel: 800-835-4709 or 240-402-7800; E-mail: ocod@fda.hhs.gov
<http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/default.htm>

or

Office of Orphan Products Development
Office of Special Medical Programs
Office of the Commissioner
Food and Drug Administration
10903 New Hampshire Ave, Bldg. 32, rm. 5295
Silver Spring, MD, 20993

Tel: 301-796-8660; E-mail: orphan@fda.hhs.gov
<http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/default.htm>

**U.S. Department of Health and Human Services
Food and Drug Administration
Center for Biologics Evaluation and Research (CBER)
Center for Drug Evaluation and Research (CDER)
Office of Orphan Products Development (OOPD)**

November 17, 2014

TABLE OF CONTENTS

I.	INTRODUCTION.....	1
II.	BACKGROUND AND OVERVIEW	1
III.	DEFINITIONS, POLICIES, AND PROCEDURES — QUESTIONS AND ANSWERS.....	3
A.	Rare Pediatric Disease Product Applications.....	3
B.	Requesting Rare Pediatric Disease Designation.....	7
C.	Requesting a Rare Pediatric Disease Priority Review Voucher	13
D.	Using and Transferring a Rare Pediatric Disease Priority Review Voucher	16
E.	Specific Eligibility Questions.....	19
F.	Relationship between Rare Pediatric Disease Designation and Orphan-Drug Designation.....	20
G.	Agency's Responsibilities and Roles.....	21

Contains Nonbinding Recommendations

Draft – Not for Implementation

**Rare Pediatric Disease Priority Review Vouchers,
Guidance for Industry¹:**

This draft guidance, when finalized, will represent the Food and Drug Administration’s (FDA’s) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the FDA staff responsible for implementing this guidance. If you cannot identify the appropriate FDA staff, call the appropriate number listed on the title page of this guidance.

I. INTRODUCTION

This guidance provides information on the implementation of section 908 of the Food and Drug Administration Safety and Innovation Act (FDASIA),² which added section 529 to the Federal Food, Drug, and Cosmetic Act (the FD&C Act).³ Under section 529, FDA will award priority review vouchers to sponsors of certain rare pediatric disease product applications that meet the criteria specified in that section.

FDA’s guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in Agency guidances means that something is suggested or recommended, but not required.

II. BACKGROUND AND OVERVIEW

Section 529 of the FD&C Act is intended to encourage development of new drug and biological products (“drugs”) for prevention and treatment of certain rare pediatric diseases. Although there are existing incentive programs to encourage the development and study of drugs for rare diseases, pediatric populations, and unmet medical needs, section 529 provides an additional incentive for rare pediatric diseases, which may be used alone or in combination with other incentive programs. These other incentive programs include: orphan-drug designation and the

¹ This guidance has been prepared by the Center for Biologics Evaluation and Research (CBER), the Center for Drug Evaluation and Research (CDER), and the Office of Orphan Products Development (OOPD).

² Public Law 112-144, enacted July 9, 2012.

³ 21 U.S.C. 360ff. Unless otherwise noted, references to “sections” in this guidance are to sections of the FD&C Act.

Contains Nonbinding Recommendations

Draft – Not for Implementation

associated benefits under the Orphan Drug Act for rare disease therapies;⁴ programs that encourage or require the study of drugs used in pediatric populations under the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA);⁵ and various programs to facilitate and expedite development and review of new drugs to address unmet medical needs in the treatment of serious or life-threatening conditions.⁶ Even so, Congress has recognized that there remain unmet medical needs among patients with rare diseases that occur primarily in pediatric populations. By enacting section 529, Congress intended to stimulate new drug development for rare pediatric diseases by offering additional incentives for obtaining FDA approval of these products.

Under section 529, the sponsor of a human drug application (as defined in section 735(1) of the FD&C Act⁷) for a rare pediatric disease drug product may be eligible for a voucher that can be used to obtain a priority review for a subsequent human drug application submitted under section 505(b)(1) of the FD&C Act⁸ or section 351 of the Public Health Service (PHS) Act after the date of approval of the rare pediatric disease drug product.

This guidance is intended to assist developers of rare pediatric disease products in assessing whether their product may be eligible for rare pediatric disease designation and a rare pediatric

⁴ Public Law 97-414, as amended, codified at sections 526-528 of the FD&C Act (21 U.S.C. 360aa-360ee).

⁵ See, e.g., Public Law 107-109 (January 4, 2002) and Public Law 108-155 (December 3, 2003), codified in sections 505A and 505B of the FD&C Act (21 U.S.C. 355a-355c).

⁶ These programs include, among others, fast track designation, breakthrough therapy designation, accelerated approval, priority review designation, and programs for certain tropical disease products and antibiotics. For more information, you may refer to the FDA Guidance, Expedited Programs for Serious Conditions – Drugs and Biologics, available at

<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM358301.pdf>; FDA Draft Guidance, Neglected Tropical Diseases of the Developing World: Developing Drugs for Treatment or Prevention, available at

<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM269221.pdf>; FDA Draft Guidance, Tropical Disease Priority Review Vouchers, available at

<http://www.fda.gov/downloads/Drugs/Guidances/UCM080599.pdf>; and Food and Drug Administration Innovation and Safety Act (FDASIA), Public Law 112-144, Title VIII—Generating Antibiotic Incentives Now.

⁷ This is the statutory definition:

(1) The term “human drug application” means an application for--

(A) approval of a new drug submitted under section 355(b) of this title, or

(B) licensure of a biological product under subsection (a) of section 262 of Title 42.

Such term does not include a supplement to such an application, does not include an application with respect to whole blood or a blood component for transfusion, does not include an application with respect to a bovine blood product for topical application licensed before September 1, 1992, an allergenic extract product, or an in vitro diagnostic biologic product licensed under section 262 of Title 42, does not include an application with respect to a large volume parenteral drug product approved before September 1, 1992, does not include an application for a licensure of a biological product for further manufacturing use only, and does not include an application or supplement submitted by a State or Federal Government entity for a drug that is not distributed commercially. Such term does include an application for licensure, as described in subparagraph (B), of a large volume biological product intended for single dose injection for intravenous use or infusion.

Section 735(1) of the FD&C Act (21 U.S.C. 379g(1)).

⁸ Because 505(b)(2) new drug applications (NDAs) are submitted under section 505(b)(1), all references to NDAs submitted under section 505(b)(1) include 505(b)(2) applications.

Contains Nonbinding Recommendations

Draft – Not for Implementation

disease priority review voucher. It also clarifies the process for requesting such designations and vouchers, sponsor responsibilities upon approval of a rare pediatric disease product application, and the parameters for using and transferring a rare pediatric disease priority review voucher.

III. DEFINITIONS, POLICIES, AND PROCEDURES — QUESTIONS AND ANSWERS

A. Rare Pediatric Disease Product Applications

Q1. What is a “rare pediatric disease”?

“*Rare pediatric disease*” is defined at section 529(a)(3) as a disease that:

- “primarily affects individuals aged from birth to 18 years, including age groups often called neonates, infants, children, and adolescents,” which we⁹ interpret as meaning that greater than 50% of the affected population in the U.S. is aged 0 through 18 years;¹⁰ *and*
- is “a rare disease or condition” as defined in section 526, which includes diseases and conditions that affect fewer than 200,000 persons in the United States (U.S.) and diseases and conditions that affect a larger number of persons and for which there is no reasonable expectation that the costs of developing and making available the drug in the U.S. can be recovered from sales of the drug in the U.S.

Of note, section 529 describes the pediatric population as from birth through 18 years. This age range differs from how FDA defines the pediatric population in other contexts. Generally, for drug and biological products, FDA considers the pediatric population to include patients from birth through 16 years.¹¹

Under our interpretation of section 529(a)(3), a drug would qualify as a drug for a “rare pediatric disease” if the entire prevalence of the disease or condition in the U.S. is below 200,000 and if more than 50% of patients with the disease are 0 through 18 years of age. Another way a drug may qualify as a drug for a “rare pediatric disease” is if it is for an “orphan subset” of a disease or condition that otherwise affects 200,000 or more persons in the U.S., and if this subset is primarily (i.e., more than 50%) comprised of individuals aged 0 through 18 years.¹²

⁹ Throughout this document, we use the terms “we” and “FDA” interchangeably.

¹⁰ We interpret “from birth to 18 years” as including all individuals less than 19 years of age (i.e., as from 0 through 18 years). This is consistent with how FDA interprets 21 CFR 201.57(c)(9)(iv), which describes a pediatric age range as “from birth to 16 years” and which we interpret as including all individuals less than 17 years of age (i.e., as from 0 through 16 years).

¹¹ See 21 CFR 201.57(c)(9)(iv).

¹² An “orphan subset” requires demonstration that use of the drug outside of the subset of interest (in the remaining persons with the disease or condition) would not be appropriate owing to one or more properties of the drug, such as drug toxicity, mechanism of action, or previous clinical experience with the drug. See 21 CFR 316.3(b)(13); 21 CFR 316.20(b)(6). A drug may qualify as a drug for a “rare pediatric disease” based on one of two possible “orphan subset” demonstrations: (i) an “orphan subset” of a non-rare disease or condition, if this subset is under the 200,000 prevalence limit and more than 50% of the prevalence is aged 0 through 18 years; or (ii) an “orphan subset” of the

Contains Nonbinding Recommendations

Draft – Not for Implementation

The calculation of prevalence estimates will depend on whether the drug is a therapeutic drug or a vaccine, diagnostic drug, or preventive drug, as follows:

- *For therapeutic drugs*, prevalence estimates of the entire affected U.S. population and of those aged 0 through 18 years should be based on the number of individuals diagnosed with the disease or condition. For some diseases and conditions, individuals may have an underlying genetic abnormality at birth but may not develop manifestations of the disease until later, if ever. In these instances, whether individuals are considered “diagnosed” for the purpose of estimating prevalence may depend on whether the product is intended to treat an underlying genetic abnormality, attenuate or prevent progression of the clinical expression of the disease, or treat the clinical symptoms or manifestations of the disease.
- *For vaccines, diagnostic drugs, and preventive drugs*, prevalence estimates should be based on the number of persons of all ages, and those 0 through 18 years of age, to whom the drug will be administered in the U.S annually.

For information on how to document prevalence in designation requests, see the responses to Questions 8 and 14.

Qualifying as a drug for a “rare pediatric disease” is not sufficient to receive a priority review voucher. For sponsors to receive such a voucher, the application for the drug must meet all of the remaining eligibility criteria described in response to Question 2.

Q2. What is a “rare pediatric disease product application”?

The term *rare pediatric disease product application* is defined in section 529(a)(4) of the FD&C Act. It refers to an application that:

- Is a human drug application as defined in section 735(1) of the FD&C Act¹³:
 - For prevention or treatment of a *rare pediatric disease* (see Question 1);
 - That contains no active ingredient (including any ester or salt of the active ingredient) that has been previously approved in any other application under section 505(b)(1), 505(b)(2), or 505(j) of the FD&C Act or section 351(a) or 351(k) of the PHS Act.
- That FDA deems eligible for priority review (see Question 15).¹⁴

affected age range if the drug is for a rare disease or condition that does not primarily affect individuals aged 0 through 18 years, but if the drug would only be used primarily in that age range owing to one or more properties of the drug. See also Question 8, item (9).

¹³ See footnote 7.

¹⁴ For more information on priority review, you may refer to FDA Draft Guidance, Expedited Programs for Serious Conditions – Drugs and Biologics, available at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM358301.pdf>.

Contains Nonbinding Recommendations

Draft – Not for Implementation

- Is submitted under section 505(b)(1) of the FD&C Act¹⁵ or section 351(a) of the Public Health Service Act.
- Relies on clinical data derived from studies examining a pediatric population and dosages of the drug intended for that population (see Question 3).
- Does not seek approval for an adult indication in the original rare pediatric disease product application (see Question 4); and
- Is approved after the date of enactment of the Prescription Drug User Fee Amendments of 2012 (July 9, 2012).¹⁶

Q3. What does “Relies on clinical data derived from studies examining a pediatric population and dosages of the drug intended for that population” mean?

As noted in the response to Question 2, an applicant cannot receive a rare pediatric disease priority review voucher unless, among other things, the application “[r]elies on clinical data derived from studies examining a pediatric population and dosages of the drug intended for that population.” We interpret this clause to mean that, to be eligible for a voucher, the approved product:

- must have been studied in a pediatric population with the rare disease (although the studies may also include adults in appropriate circumstances), and
- must be adequately labeled for the pediatric population in terms of safety, effectiveness, and dosage information.

It is important that applicants seeking a voucher submit data adequate for labeling the drug for use by the full range of affected pediatric patients (i.e., all pediatric patient age ranges that are affected by the disease). Such labeling aligns with the intent of section 529, which is to help address the unmet medical needs of pediatric patients with rare pediatric diseases.

Q4. What does “Does not seek approval for an adult indication in the original rare pediatric disease product application” mean?

See also

<http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/SpeedingAccessToImportantNewTherapies/ucm128291.htm#priorityreview>.

¹⁵ See footnote 8.

¹⁶ Note that there are limitations on when vouchers can be awarded: No voucher may be awarded if the application was submitted to FDA prior to October 7, 2012 (i.e., 90 days after enactment of the Prescription Drug User Fee Amendments (PDUFA) of 2012), section 529(b)(3), and no voucher may be issued after the last day of the 1-year period that begins on the day FDA awards the third voucher under this program, section 529(b)(5).

Contains Nonbinding Recommendations

Draft – Not for Implementation

An applicant cannot receive a rare pediatric disease priority review voucher if the application seeks approval for an adult indication in the original rare pediatric disease product application. We interpret this criterion to mean that, to preserve voucher eligibility, the applicant cannot seek approval for a *different* adult indication (i.e., for a different disease/condition) in the original rare pediatric disease application. If the applicant seeks approval for use by pediatric and adult populations with the rare pediatric disease, the applicant will still be eligible for a voucher if the approved use includes pediatric use, as described in Question 3. If the applicant obtains approval for use *only* in an adult population with the rare pediatric disease, the applicant is ineligible for a voucher.

Thus, under this interpretation, an applicant can preserve voucher eligibility even if the applicant seeks approval for use by adults in addition to pediatric patients with the rare pediatric disease. One reason we are interpreting the statute in this way is to avoid incentivizing sponsors to exclude adults affected by the rare pediatric disease from clinical trials or to exclude adult data from the subsequent marketing application solely for the sake of voucher eligibility, when such exclusions may not be scientifically or ethically acceptable for the reasons described below.

Clinical Trial Design – Clinical Trials for a Potential Rare Pediatric Disease Product May Need to Include Individuals Over 18 Years of Age for Scientific or Ethical Reasons: Clinical trials for rare diseases and conditions are challenging because, among other factors, the small patient populations limit the opportunities for study and verification of results. Because such clinical trials are likely to be small and at risk of being underpowered, FDA expects that rare disease clinical development programs will attempt to include all patients with the rare disease or condition that are available for study and who could reasonably be expected to benefit from the intervention, regardless of the age of the patient (where feasible and appropriate based on the disease/condition and expected effects of intervention).¹⁷ Indeed, studies using novel therapies should generally be conducted in young adults (18 to 21 years of age) prior to exposing adolescents and younger pediatric patients; for children to be included in early phase investigations, there must be a prospect of direct benefit for an individual child to be studied in a clinical trial in which more than a minor increase over minimal risk is presented by an intervention or procedure.¹⁸ For all of these reasons, it may not be scientifically or ethically appropriate to exclude those over 18 years of age from a clinical trial evaluating a potential rare pediatric disease product.

Data to Include in a Marketing Application – Available Adult Safety and Effectiveness Data Must be Included in the Application: If clinical safety and effectiveness data are available in an adult population (i.e., individuals over 18 years) at the time of the submission of an original application for a potential rare pediatric disease product, these data must be included in the application for FDA's review.¹⁹ In many cases, if there is a population over 18 years

¹⁷ See, e.g., ICH and FDA Guidance, "E11 Clinical Investigation of Medicinal Products in the Pediatric Population," Section II.A, available at <http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm129477.pdf>.

¹⁸ 21 CFR 50.52 and 50.53; see also ICH and FDA Guidance, "E11 Clinical Investigation of Medicinal Products in the Pediatric Population," footnote 17, Section II.C.

¹⁹ 21 CFR 314.50(d)(5)(iv); 21 CFR 601.2. ²⁰ 21 U.S.C. 379h.

Contains Nonbinding Recommendations

Draft – Not for Implementation

of age with the rare pediatric disease that could benefit from the product and for whom there are available data to support the evaluation of the safety and effectiveness of the product, labeling for such a population should be sought in the original product application.

As noted, seeking approval for use in both adults and pediatric patients with the rare pediatric disease will not affect voucher eligibility. However, we remind applicants seeking a voucher that – whether or not they seek approval for use in an adult population – we expect them to submit data adequate for labeling the drug for use by the full range of affected pediatric patients (see response to Question 3).

Q5. What user fees apply to a rare pediatric disease product application?

User fees for human drug applications are described in section 736 of the FD&C Act.²⁰ In general, a rare pediatric disease product application is subject to these statutory requirements like any other application. Such applications may, however, be eligible for exemptions from some fees if they have received orphan-drug designation. See FDA’s Guidance for Industry User Fee Waivers, Reductions, and Refunds for Drug and Biological Products.²¹

User fees also apply to applications for which a rare pediatric disease priority review voucher is used, as described in Question 21.

Q6. What are the sponsor’s responsibilities after approval of a rare pediatric disease product application?

The sponsor of an approved rare pediatric disease product application must submit a report to FDA no later than 5 years after approval that addresses, for each of the first 4 post-approval years:

- the estimated population in the U.S. with the rare pediatric disease for which the product was approved (both the entire population and the population aged 0 through 18 years),
- the estimated demand in the U.S. for the product, and
- the actual amount of product distributed in the U.S.

Section 529(e)(2). Sponsors should submit such reports to the review division within FDA that reviewed the new drug application (NDA)/ biologics license application (BLA) for the rare pediatric disease product. This report should be prominently marked, “Rare Pediatric Disease Product Post-Approval Report.”

B. Requesting Rare Pediatric Disease Designation

Q7. What is the rare pediatric disease designation process?

²⁰ 21 U.S.C. 379h.

²¹ Available at

<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079298.pdf>.

Contains Nonbinding Recommendations

Draft – Not for Implementation

Under section 529(d), a sponsor may choose to request rare pediatric disease designation. This designation process is entirely voluntary; requesting designation is not a prerequisite to requesting or receiving a priority review voucher.

If sponsors choose to request such designation, section 529(d)(2) provides that they shall do so “at the same time” that they submit a request for orphan-drug designation under section 526²² or a request for fast track designation under section 506.²³

Note that, while a request for rare pediatric disease designation may be submitted at the same time as a request for orphan-drug designation or fast track designation, each request should be submitted as a separate proposal (i.e., they should not be submitted in one combined package). See Question 9 for how to submit a rare pediatric disease designation request.

We remind sponsors of the timing for orphan-drug and fast track designation requests:

Timing of Requests for Orphan-Drug Designation: Under section 526, orphan-drug designation requests must be submitted before the sponsor’s filing of a marketing application for the drug for the orphan use.²⁴

Timing of Requests for Fast Track Designation: Requests for fast track designation may be submitted at the time of original submission of the investigational new drug (IND) application or any time thereafter prior to receiving marketing approval of the NDA or BLA, although FDA encourages that such requests be submitted no later than the sponsor’s pre-NDA/BLA meeting because many of the benefits of fast track designation will no longer be applicable after that time.²⁵

If sponsors submit a timely request for rare pediatric disease designation, section 529(d)(3) directs FDA to make a decision on the request no later than 60 days after submission.²⁶ The

²² 21 U.S.C. 360bb.

²³ 21 U.S.C. 356.

²⁴ For more information on orphan-drug designation, see 21 CFR part 316 and <http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/HowtoapplyforOrphanProductDesignation/default.htm>.

²⁵ These benefits include more frequent meetings with FDA and written correspondence from FDA on the drug development plan and clinical data collection, rolling review of portions of the marketing application before receipt of the complete application, and the possibility of accelerated approval (i.e., approval based on an effect on a substitute endpoint or intermediate clinical endpoint reasonably likely to predict clinical benefit). For more information on fast track designation and accelerated approval, see FDA Guidance, Expedited Programs for Serious Conditions—Drugs and Biologics, available at:

<http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm358301.pdf>.

See also

<http://www.fda.gov/forconsumers/byaudience/forpatientadvocates/speedingaccesstoimportantnewtherapies/ucm128291.htm>.

²⁶ FDA interprets this language, “not later than 60 days after the request is submitted,” to mean that FDA must respond within 60 days after receiving the request.

Contains Nonbinding Recommendations

Draft – Not for Implementation

statute directs FDA to decide whether to designate the drug as a drug for a “rare pediatric disease” *and* whether to designate the application for the drug as “a rare pediatric disease product application,”²⁷ as described in response to Question 10.

FDA recognizes that some sponsors may wish to submit a rare pediatric disease designation request at a different time – for example, if they had already submitted requests for orphan-drug and/or fast track designation before the enactment of FDASIA, or if for whatever reason they have no interest in submitting either such request but do want to submit a rare pediatric disease designation request. FDA is willing to accept designation requests submitted at a different time than that provided by statute as long as FDA receives the designation request before FDA has filed the NDA/BLA for the drug for the relevant indication. Although we will aim to respond to such requests in a timely manner, the 60-day response deadline does not apply. We will not accept requests for rare pediatric disease designation received after FDA has already filed the NDA/BLA for the drug for the relevant indication.

Even if sponsors have requested and received rare pediatric disease designation, they should include a request for a rare pediatric disease priority review voucher in their original NDA/BLA submission (either in the initial package sent or up until the point of NDA/BLA filing). Sponsors who have not requested designation, or have not received designation, may also request a voucher in their original NDA/BLA submission. See responses to Questions 13 and 14 for information on requesting such a voucher.

Q8. What information should these designation requests contain?

Sponsors should include the following information in rare pediatric disease designation requests:

- (1) The name and address of the sponsor and the name of the sponsor’s primary contact person and/or resident agent including title, address, telephone number, and email address;
- (2) The non-proprietary and trade name, if any, of the drug, or, if neither is available, the chemical name or a meaningful descriptive name of the drug;
- (3) The proposed dosage form and route of administration;
- (4) A description of the rare pediatric disease for which the drug is being or will be investigated; the proposed use of the drug; and the IND number if previously assigned;
- (5) A description of the drug to include (i) the identity of the active moiety, if it is a drug composed of small molecules, or of the principal molecular structural features, if it is composed of macromolecules, or the active ingredient if it is a biological product; and (ii) its physical and chemical properties, if these characteristics can be determined;

²⁷ See section 529(d)(3).

Contains Nonbinding Recommendations

Draft – Not for Implementation

(6) An explanation of the mechanism of action, with supportive data, suggesting that the drug may be effective in the rare pediatric disease;²⁸

(7) The basis for concluding that the drug is for a “rare disease or condition.” This basis is established when a sponsor provides the following information, as described in Section 526 of the FD&C Act:²⁹

(i) Documentation, with appended authoritative references, to demonstrate that (a) the estimated prevalence of the affected patient population in the U.S. – those diagnosed with the disease or condition – is below 200,000 at the time of submission of the request for designation, or (b) if the drug is a vaccine, diagnostic drug, or preventive drug, the persons to whom the drug will be administered in the U.S. are fewer than 200,000 per year. Please provide a list of sources for the information, including dates of the information provided and literature citations (see response to Question 2 for more on estimating prevalence); or

(ii) For drugs intended for diseases or conditions affecting 200,000 or more people in the U.S., or for a vaccine, diagnostic drug, or preventive drug that would be given to 200,000 or more persons in the U.S. per year, a summary of the sponsor’s basis for believing that the disease or condition occurs so infrequently that there is no reasonable expectation that the costs of drug development and marketing will be recovered in future sales of the drug in the U.S. We ask that sponsors include the same sort of cost and related information as is detailed at 21 CFR 316.21(c).

(8) Documentation, with appended authoritative references, to demonstrate that the rare disease or condition for which the drug is proposed is a “rare pediatric disease” as defined in section 529(a)(3), meaning that more than 50% of the estimated prevalence in the U.S. is 0 through 18 years of age (see response to Question 2). If the drug is a vaccine, diagnostic drug, or preventive drug, documentation, with appended authoritative references, to demonstrate that more than 50% of the persons to whom the drug will be administered in the U.S. will be 0 through 18 years. Please provide a list of sources for the information, including dates of the information provided and literature citations.

(9) Where a sponsor requests designation of a drug (i) for only a subset of persons with a particular disease or condition that otherwise affects 200,000 or more people (“orphan subset” of non-rare disease or condition), or (ii) for only a pediatric subset of a disease or condition that affects fewer than 200,000 but otherwise does not primarily affect individuals 0 through 18 years of age (effectively an “orphan subset” of the age range), a demonstration that, due to one or more properties of the drug, the remaining persons with

²⁸ As explained in response to Question 29, FDA expects a lesser level of supportive data for rare pediatric disease designation than for orphan-drug designation because of the many differences between the two programs. In vitro data supporting the mechanism of action of the drug in the disease or in a related disease may suffice for rare pediatric disease designation, whereas that level of data would not generally suffice for orphan-drug designation.

²⁹ See 21 CFR 316.20.

Contains Nonbinding Recommendations

Draft – Not for Implementation

such disease or condition would not be appropriate candidates for use of the drug (see Question 1 and footnote 12). Such properties of the drug may include drug toxicity, mechanism of action, or previous clinical experience with the drug.

(10) Explanation as to whether, upon approval, the drug may potentially meet the voucher eligibility criterion of containing no previously approved active ingredient (including any ester or salt of the active ingredient).

If sponsors are submitting a rare pediatric disease designation request at the same time as or shortly after a request for orphan-drug designation for the drug, they can cross-reference any of the above information already contained in their orphan-drug designation request.³⁰

Q9. What is the process for submitting rare pediatric disease designation requests?

Sponsors should submit two copies, with at least one hard copy, of the completed, dated, and signed rare pediatric disease designation requests, with the information specified in response to Question 8, to the Office of Orphan Products Development, Food and Drug Administration, Bldg. 32, rm. 5295, 10903 New Hampshire Ave., Silver Spring, MD 20993.

Q10. How will FDA respond to such designation requests?

The statute requires that FDA, in responding to rare pediatric disease designation requests, decide whether to designate the drug as a drug for a “rare pediatric disease” *and* whether to designate the associated marketing application as a “rare pediatric disease product application.”³¹ The Office of Orphan Products Development (OOPD) will issue the designation response in consultation with the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER), as appropriate. This designation response will take one of the following forms:

A Deficiency Letter: FDA will send a deficiency letter within the timeframe specified in Question 7 if the request lacks the information described in Question 8 or contains inaccurate or incomplete information. In the deficiency letter, we will ask the sponsor to respond within 60 days or else request an extension of time to respond within that same timeframe; otherwise, FDA may consider the designation request voluntarily withdrawn.

Designating the Drug as a Drug for a “Rare Pediatric Disease” and Either Denying or Conditionally Designating the Application as a “Rare Pediatric Disease Product Application”: FDA will designate a drug as a drug for a “rare pediatric disease” within the timeframe specified in response to Question 7 if the sponsor provides adequate information to demonstrate that the

³⁰ Cross-referencing of information in previously submitted orphan-drug designation requests may not be appropriate if the information is outdated, for example, if prevalence estimates for the disease have changed in the intervening time between submission of the orphan-drug designation request and submission of the rare pediatric disease designation request.

³¹ Section 529(d)(3)(A) and (B).

Contains Nonbinding Recommendations

Draft – Not for Implementation

drug is for a rare pediatric disease (including appropriate prevalence estimates with appended authoritative references) and an adequate explanation, with supportive data, of the drug's mechanism of action suggesting that the drug may be effective in the rare pediatric disease (see response to Question 8). FDA will evaluate prevalence as of the time of submission of the designation request. If FDA designates the drug as a drug for a "rare pediatric disease," these prevalence estimates generally will not be reevaluated at the time of NDA/BLA submission,³² but FDA will evaluate the remaining eligibility criteria to determine whether the NDA/BLA is eligible for a priority review voucher (see Question 2).

Even if FDA designates the drug as a drug for a "rare pediatric disease," FDA cannot definitively designate any associated marketing application as a "rare pediatric disease product application" because eligibility cannot be determined unless and until the application is approved or licensed. This is because eligibility depends on the contents of the application, including whether the application will contain no previously approved active ingredient (including any ester or salt of the active ingredient) (see Question 2). Short of designating the application, FDA has two options in responding to the application portion of a designation request:

(1) *to conditionally designate the application* as a "rare pediatric disease product application" assuming that, at the time of approval or licensure, it will meet all of the eligibility criteria set forth in section 529(a)(4). The final answer to a conditional designation of an application will come in the form of a voucher award or non-award at the time of marketing approval, if the sponsor requests such a voucher in the NDA/BLA. As described in responses to Questions 13 and 14, even sponsors who receive rare pediatric disease designation should include a voucher request in their original NDA/BLA submission if they remain interested in receiving a voucher.

(2) *to deny designating the application* if, at the time of submission of the designation request, it appears the application will contain a previously approved active ingredient (including any ester or salt of the active ingredient). Even sponsors who have been denied such designation may request a voucher in their NDA/BLA submission if they believe they are eligible (see responses to Questions 13 and 14).

Neither Designating the Drug as a Drug for a "Rare Pediatric Disease" Nor Designating the Application as a "Rare Pediatric Disease Product Application": If FDA determines that the drug is not in fact a drug for a "rare pediatric disease," FDA will deny rare pediatric disease designation of both the drug and the application. Reasons for such denial include:

- the drug is not for a "rare disease or condition" under section 526 (e.g., prevalence in the U.S. is 200,000 or greater), and the drug is not for an "orphan subset" of a non-rare disease or condition;

³² FDA does reserve the right to revisit a decision on prevalence estimates if it becomes apparent that information relevant to that question and available at the time of the submitted request for designation was not provided to FDA or known by FDA at the time of designation decision.

Contains Nonbinding Recommendations

Draft – Not for Implementation

- the drug is not for a disease or condition (or “orphan subset” of a disease or condition) that “primarily affects individuals aged from birth to 18 years” in the U.S. (i.e., more than 50% of the prevalence in the U.S. is over 18 years of age regardless of whether the disease or condition is an orphan or orphan subset);
- there is insufficient evidence to support the necessary prevalence estimates or to demonstrate an orphan subset;
- lack of an adequate explanation, with supportive data, of the drug’s mechanism of action suggesting that the drug may be effective in the rare pediatric disease;
- the request contains an untrue statement of material fact, omits material information, or is otherwise ineligible for designation.

Even if a sponsor is denied rare pediatric disease designation, the sponsor can request a rare pediatric disease priority review voucher at the time of NDA/BLA submission if the sponsor believes the submission is eligible (see responses to Questions 13 and 14).

Voluntarily Withdrawn Letter: FDA may consider a designation request voluntarily withdrawn if the sponsor fails to respond to a deficiency letter, or to request an extension of time to respond, within 60 days of the deficiency letter date. In the event FDA considers a request voluntarily withdrawn, FDA will notify the sponsor in writing. As above, such sponsors can still request a voucher in the NDA/BLA submission if they believe they are eligible.

Not Accepted Letter: As noted in response to Question 7, FDA will not accept requests for rare pediatric disease designation received after FDA has already filed the NDA/BLA for the drug for the relevant indication. Such sponsors may still receive a voucher if they request a voucher in the NDA/BLA submission and they are otherwise eligible.

Q11. What if a sponsor chooses not to submit a rare pediatric disease designation request before submitting the marketing application?

Sponsors who choose not to submit a rare pediatric disease designation request may nonetheless receive a priority review voucher if they request such a voucher in their original marketing application and meet all of the eligibility criteria. The determination of whether the drug is for a “rare pediatric disease” (i.e., based on total prevalence in the U.S. and prevalence of those aged 0 through 18 years) will occur as described above, except the prevalence determination will be based on the prevalence at the time of NDA/BLA submission rather than the prevalence at the time of designation request.

We encourage sponsors who are interested in receiving a rare pediatric disease priority review voucher to notify FDA early of their interest (e.g., in a pre-NDA/BLA meeting). However, notification before submission of the rare pediatric disease product application is not required. The process for requesting a voucher at the time of NDA/BLA submission is described in Questions 13 and 14.

C. Requesting a Rare Pediatric Disease Priority Review Voucher

Contains Nonbinding Recommendations

Draft – Not for Implementation

Q12. Do sponsors need to receive rare pediatric disease designation before requesting a priority review voucher?

No. As noted in response to Question 7, rare pediatric disease designation is entirely voluntary. Sponsors need not receive designation before requesting a rare pediatric disease priority review voucher.

Q13. When should sponsors request a rare pediatric disease priority review voucher?

Whether or not sponsors have requested rare pediatric disease designation, sponsors seeking a rare pediatric priority review voucher should submit a voucher request in the original submission of the potential rare pediatric disease product application – either in the initial package sent or up until the point of NDA/BLA filing. This voucher request should be prominently marked, “Rare Pediatric Disease Priority Review Voucher Request,” and be included or referenced in a cover letter.³³

Q14. What information should sponsors include in a priority review voucher request?

This request for a voucher should describe how the application meets the eligibility criteria described in response to Question 2. The contents of this request will depend on whether the sponsor has already received rare pediatric disease designation, as follows:

Sponsors Who Have Received Rare Pediatric Disease Designation for the Drug and Conditional Designation for the Application: Sponsors who have received rare pediatric disease designation for the drug and conditional designation for the application should include that designation letter with the voucher request and need not re-analyze prevalence estimates at the time of NDA/BLA submission. The request should explain how the application meets all of the remaining eligibility criteria described in response to Question 2.

Sponsors Who Have Received Rare Pediatric Disease Designation for the Drug but Have Been Denied Designation for the Application: As noted, some sponsors may receive rare pediatric disease designation for the drug, but be denied designation for the application if it appears that the same active ingredient (including any ester or salt of the active ingredient) has been previously approved. These sponsors may still seek a voucher at the time of NDA/BLA submission if, at that time, they believe their application in fact contains no previously approved active ingredient (including any ester or salt of the active ingredient). In any such voucher

³³ Although the statute does not require that sponsors submit such requests in order to receive a rare pediatric disease priority review voucher (if eligible), we strongly encourage sponsors to do so. Submitting such requests serves both the sponsor’s interest and FDA’s interest, by helping ensure that FDA has the necessary information to evaluate voucher eligibility and does not inadvertently overlook eligible applications. In the event that a sponsor has not submitted a voucher request but it otherwise comes to FDA’s attention that the sponsor may be eligible to receive a rare pediatric disease priority review voucher, FDA intends to notify the sponsor of this possible eligibility and request that the sponsor submit supporting information within 60 days, to include prevalence estimates of the disease/condition in the U.S. and those aged 0 through 18 years (with supporting documentation described in Question 8 items (7)-(8)).

Contains Nonbinding Recommendations

Draft – Not for Implementation

request, sponsors should explain why they believe they are eligible for a voucher, including how they meet this “no previously approved active ingredient” criterion and the other criteria listed in the response to Question 2. To show that their drug is for a “rare pediatric disease,” they should include their drug designation letter and need not re-analyze prevalence estimates at the time of NDA/BLA submission.

Sponsors Who Have Requested but Not Received Rare Pediatric Disease Designation for the Drug or Application: Sponsors who have requested but not received rare pediatric disease designation should include in a voucher request the latest designation correspondence from FDA (i.e., an acknowledgment letter, deficiency letter, denial letter, or voluntarily withdrawn letter). If the designation request has been denied or withdrawn, then the voucher request should include new prevalence estimates as of the time of NDA/BLA submission; otherwise, the sponsor can cross-reference the information in its designation request and provide additional information as necessary. In particular:

- Sponsors who have received only an *acknowledgment letter* in response to a designation request should cross-reference their designation request (with associated prevalence estimates) and explain how their applications meet all the remaining eligibility criteria described in response to Question 2.
- Sponsors who have received a *deficiency letter* should include a response to the deficiency letter with their voucher requests or else cross-reference a previously submitted deficiency response, in addition to explaining how their applications meet the remaining eligibility criteria for a voucher.³⁴
- Sponsors who have received *denial letters* should explain how their drug is for a “rare pediatric disease” despite this denial, based on new information about the drug or the disease/condition, and include new prevalence estimates as of the time of NDA/BLA submission (with supporting documentation described in Question 8 items (7)-(8)). They should also explain how their applications meet all of the remaining eligibility criteria for a voucher.
- Sponsors who have received *voluntarily withdrawn letters* should likewise include new prevalence estimates as of the time of NDA/BLA submission (with supporting documentation described in Question 8 items (7)-(8)) and explain how their applications meet the remaining eligibility criteria for a voucher.

Sponsors Who Have Not Requested Rare Pediatric Disease Designation: Sponsors who have not requested rare pediatric disease designation should include in a voucher request prevalence estimates as of the time of NDA/BLA submission, with supporting documentation described in Question 8 items (7)-(8), and explain how the application meets all of the remaining eligibility criteria described in the response to Question 2.

³⁴ As noted in response to Question 31, OOPD will evaluate the prevalence estimates in consultation with CDER and CBER, as appropriate; the review division within CDER and CBER will evaluate whether the application meets the remaining eligibility criteria for receiving a voucher.

Contains Nonbinding Recommendations

Draft – Not for Implementation

D. Using and Transferring a Rare Pediatric Disease Priority Review Voucher

Q15. What is a priority review?

When a marketing application receives priority review designation, FDA’s goal is to take action on the application within 6 months as compared to 10 months for a standard review.³⁵ An application for a drug is eligible for a priority review, absent the use of a priority review voucher, if it is determined that the drug treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. Also eligible for priority review are: any supplement that proposes a labeling change pursuant to a report on a pediatric study under section 505A; an application for a drug that has been designated as a qualified infectious disease product; or an application or supplement for a drug submitted with a priority review voucher.³⁶

Q16. What is a priority review voucher and when is it awarded?

Under section 529(a)(2) of the FD&C Act, a *priority review voucher* is a voucher that FDA issues to the sponsor of a rare pediatric disease product application at the time of the marketing application approval. This voucher entitles the holder to designate a single human drug application submitted under section 505(b)(1) of the FD&C Act³⁷ or section 351 of the PHS Act as qualifying for a priority review. Such a subsequent application would not have to meet the usual requirements for a priority review, but it would have to be submitted after the approval of the rare pediatric disease product application.

Q17. What form will the voucher take?

We will include information related to the priority review voucher in the approval letter for the rare pediatric disease product application. This letter will include a priority review voucher identification number, which should be referenced when redeeming or transferring the voucher.

Q18. How and when can a voucher be used?

³⁵ Section 529(a)(1) states that “priority review” means review and action by FDA not later than 6 months after receipt by FDA of the application “as described in the Manual of Policies and Procedures of the Food and Drug Administration and goals identified in the letters described in section 101(b) of the Prescription Drug User Fee Amendments [PDUFA] of 2012.” The goals letters associated with the 2012 PDUFA commit FDA to approving 90% of applications designated as priority within the 6-month period, and include the stipulation that the 6-month and 10-month commitments for new drug applications containing new molecular entities and original biologic license applications start after the 60-day filing period for the application. (The period for new drug applications not containing new molecular entities starts on the date of receipt.) *See* <http://www.fda.gov/downloads/forindustry/userfees/prescriptiondruguserfee/ucm270412.pdf>.

³⁶ For more on priority review, you may refer to the FDA Draft Guidance, Expedited Programs for Serious Conditions – Drugs and Biologics, *available at* <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM358301.pdf>. *See also*

<http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/SpeedingAccessToImportantNewTherapies/ucm128291.htm#priorityreview>.

³⁷ *See* footnote 8.

Contains Nonbinding Recommendations

Draft – Not for Implementation

The application using the priority review voucher must be submitted under section 505(b)(1) of the FD&C Act³⁸ or section 351 of the PHS Act, and is not limited to drug products for rare pediatric diseases. The sponsor redeeming the voucher must notify FDA of its intent to submit an application with a priority review voucher at least 90 days before submission of the application, and must include the date the sponsor intends to submit the application (hereinafter “the intended submission date”). Section 529(b)(4)(A). This notification should be prominently marked, “Notification of Intent to Submit an Application with a Rare Pediatric Disease Priority Review Voucher.” Upon submitting this notification to FDA, the sponsor is obligated to pay the priority review user fee described in the response to Question 21. Section 529(c)(4)(A).

The voucher cannot be used if the application is submitted before the intended submission date. If a sponsor does not submit the application on the intended submission date, the sponsor should inform FDA as soon as possible of the new intended submission date. If the sponsor decides not to use the voucher for the application described in the notification, the sponsor should withdraw the notification from FDA. The sponsor should submit a new notification informing FDA, at least 90 days before application submission, of its intent to submit a different human drug application with a priority review voucher and include the intended submission date. Section 529(b)(4)(A).

Q19. Will these vouchers be transferable?

Yes. The sponsor of a rare pediatric disease drug product receiving a priority review voucher may transfer (including by sale) the voucher to another sponsor. Section 529(b)(2). The voucher may be further transferred any number of times before the voucher is used, as long as the sponsor making the transfer has not yet submitted the application. Section 529(b)(4)(B).

Q20. What is the procedure for voucher transfer?

Each person to whom a voucher is transferred must notify FDA of the change of voucher ownership within 30 days after the transfer. Section 529(b)(2)(B). This notification should be prominently marked, “Transfer of Rare Pediatric Disease Priority Review Voucher” and submitted to the NDA/BLA. It should include a letter from the previous owner to the current owner and a letter from the current owner to the previous owner, each acknowledging the transfer. Any sponsor redeeming a voucher should include these transfer letters in the application submitted to FDA (in addition to notifying FDA of the intent to submit an application with a priority review voucher, as described in response to Question 18). A complete record of transfer must be made available to FDA in order to redeem a transferred voucher.

Q21. What fees apply when using a priority review voucher?

The sponsor of a human drug application that is the subject of a priority review voucher must pay a priority review user fee in addition to any other required user fee. The amount of the

³⁸ See footnote 8.

Contains Nonbinding Recommendations

Draft – Not for Implementation

priority review user fee will be determined each fiscal year and is based on the difference between the average costs incurred by FDA, in the previous fiscal year, of reviewing a priority review NDA/BLA and an NDA/BLA that is not subject to priority review. Payment of this extra fee, to which the sponsor is legally committed as a result of the notification of its intent to use the voucher, is not subject to waivers, exemptions, reductions, or refunds. Section 529(c)(2) & (c)(4)(C).

FDA will establish the fee amount before the beginning of each fiscal year and will publish the fee schedule in the *Federal Register*.

Q22. When do I pay the priority review voucher user fee?

The priority review voucher user fee is due upon notifying FDA of the intent to submit an application with a priority review voucher, as described in the response to Question 18. Section 529(c)(4)(A). It is payable in accordance with procedures established by FDA, which will be described in the *Federal Register* notice that sets the fees for each fiscal year.³⁹ The application will be considered incomplete if the priority review voucher user fee and all other applicable user fees are not paid in accordance with FDA payment procedures. Section 529(c)(4)(B).

Q23. If I present a voucher to FDA for priority review, am I guaranteed a 6-month review on my drug application?

Although FDA's goal is to take action on the application within 6 months after the 60 day filing period for an application involving a new molecular entity or within 6 months after the date of receipt of an application not involving a new molecular entity,⁴⁰ this timeframe is not guaranteed. Note that "take action" in this context means that FDA aims to complete its review of the filed application and issue an approval or complete response letter within this timeframe; it does not mean that the application will be approved within this timeframe.

E. Specific Eligibility Questions

Q24. Is eligibility for a priority review voucher affected by whether the sponsor intends to market the rare pediatric disease drug product after approval?

The statute does not describe marketing of a rare pediatric disease drug product as a prerequisite to receiving a priority review voucher. However, under section 529(e)(1), FDA may revoke any priority review voucher if the rare pediatric disease drug product for which the voucher was awarded is not marketed in the U.S. within 1 year following the date of approval.

³⁹ The notice for fiscal year 2015 states that payment will be required after appropriations language permitting collection of fees has been enacted.

⁴⁰ See footnote 35.

Contains Nonbinding Recommendations

Draft – Not for Implementation

Q25. Are drug products eligible for a priority review voucher if they have been approved and used in other countries but have not been previously approved by FDA?

Yes, as long as they meet all the criteria for a rare pediatric disease product application described in section 529(a)(4) (see response to Question 2).

Q26. Is a drug that is already approved by FDA for another indication eligible for a priority review voucher for a rare pediatric disease product application?

No. As noted, for an application to qualify for a rare pediatric disease priority review voucher, it must be for a human drug that contains no active ingredient (including any ester or salt of the active ingredient) that has been previously approved in any other application under section 505(b)(1), 505(b)(2), or 505(j) of the FD&C Act or section 351(a) or 351(k) of the PHS Act.

Q27. Would a new pediatric formulation for a drug already approved for adults be eligible for a rare pediatric disease priority review voucher?

No. As noted, an application for a drug product containing a previously approved active ingredient (including any ester or salt of the active ingredient) is not eligible to receive a rare pediatric disease priority review voucher.

Q28. Would an application for a rare pediatric disease drug product submitted to FDA before enactment of PDUFA of 2012 (under FDASIA) but not yet approved qualify for a voucher?

No. The rare pediatric disease product sponsor may not receive a rare pediatric disease priority review voucher if the application was submitted to FDA prior to October 7, 2012 (90 days after the date of the enactment of PDUFA of 2012).

F. Relationship between Rare Pediatric Disease Designation and Orphan-Drug Designation

Q29. Will a drug that receives rare pediatric disease designation also qualify for orphan-drug designation?

We anticipate that many rare pediatric disease drug products will qualify for designation as orphan drugs (if such designation is sought) because a “rare pediatric disease” also must be a “rare disease or condition” as defined in section 526, including those that affect fewer than 200,000 persons in the U.S.⁴¹ There are instances, however, where a drug may qualify as a drug for a “rare pediatric disease” but not qualify for orphan-drug designation, or vice versa, as explained below. The following examples illustrate situations in which a drug might receive rare pediatric disease designation but not also immediately qualify for orphan drug designation

⁴¹ 21 U.S.C. 360bb.

Contains Nonbinding Recommendations

Draft – Not for Implementation

- Assume that a drug receives “rare pediatric disease” designation but is considered the “same drug” under the orphan drug regulations as an already approved drug for the same orphan use. 21 CFR 316.3(b)(14). This drug would not be eligible to receive orphan-drug designation absent a plausible hypothesis that it may be clinically superior to the already approved drug. 21 CFR 316.20(a) and (b)(5). *Note:* Even though this drug may receive “rare pediatric disease” designation, the application for the drug likely would not qualify as an “application for a rare pediatric disease product application” – and hence not be likely to receive a priority review voucher – because, if the drug is considered the “same drug” as a previously approved drug under the orphan drug regulations, then it will generally contain a previously approved active ingredient (including any ester or salt of the active ingredient), rendering it ineligible for a voucher under section 529.
- Assume a sponsor plans to develop a drug for a rare pediatric disease but so far has very little data suggesting that the drug may be effective in that disease (e.g., only in vitro data supporting the drug’s mechanism of action in a related disease). It is possible that this level of data may suffice for rare pediatric disease designation but generally it would not suffice for orphan-drug designation. This is because, to qualify for orphan-drug designation, an applicant must supply sufficient information to establish a medically plausible basis for expecting the drug to be effective in the prevention, diagnosis, or treatment of the rare disease or condition.⁴² The sponsor may eventually obtain orphan designation for the drug after developing or obtaining more supportive data for use of the drug for the rare disease or condition, including in vivo and/or clinical data in the rare disease or condition.

If a drug receives orphan-drug designation, it may be eligible for orphan-drug exclusivity, tax credits for qualified clinical testing, orphan product grant funding, as well as fee exemptions under section 736 of the FD&C Act. For information regarding these orphan drug incentives, please contact the OOPD at orphan@fda.hhs.gov or 301-796-8660. For information regarding user fee exemptions, please contact the User Fee staff in CDER’s Office of Management at 301-796-7900.

G. Agency’s Responsibilities and Roles

Q30. What are the Agency’s responsibilities if it issues a priority review voucher under section 529 or if it approves a drug application for which the sponsor used such a voucher?

As per section 529(f)(1), FDA will publish a notice in the *Federal Register* and on its website⁴³ within 30 days after issuing a priority review voucher under section 529 and within 30 days after approving a drug application for which the sponsor used such a voucher.

Q31. What are the different roles played by CDER, CBER, and the OOPD?

⁴² See 21 CFR 316.25(a)(2).

⁴³ <http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm375479.htm>

Contains Nonbinding Recommendations

Draft – Not for Implementation

CDER and CBER

The applicable review divisions within CDER and CBER have the responsibility for premarketing review of the rare pediatric disease product applications and for determining whether an application meets the eligibility criteria for receiving a priority review voucher. CDER and CBER will consult with OOPD as to whether a disease/condition is a “rare pediatric disease” as defined in section 529(a)(3).

OOPD

OOPD is distinct from CDER and CBER and is responsible for determining whether a drug (including a biological product) qualifies for designation as a drug for a “rare pediatric disease” as defined in section 529(a)(3), if such designation is requested. OOPD will consult with CDER and CBER on the question as appropriate. OOPD is also responsible for granting orphan-drug designation to drugs (including biological products) under section 526 and 21 CFR part 316. As noted in this guidance, whether a drug receives orphan-drug designation is a different question from whether it receives designation as a drug for a “rare pediatric disease.” Questions about either designation process should be directed to OOPD.

In the event a sponsor does not request rare pediatric disease designation but does request a rare pediatric disease priority review voucher at the time of NDA/BLA submission, the review division within CDER and CBER will consult with OOPD as to whether the disease/condition is a “rare pediatric disease” as defined in section 529(a)(3).

Q32. Whom should I contact if I have questions about a rare pediatric disease product application?

Sponsors with questions not addressed in this guidance should contact OOPD for designation-related questions and the appropriate review division within CDER or CBER for application-related questions. CDER and CBER encourage early interaction with potential sponsors on these issues (e.g., in a pre-NDA/BLA meeting).